A new working paper finds that preschool classrooms where teachers received an intervention designed to strengthen curriculum implementation, effective teaching practices, and teachers' engagement ...
Organogenesis Holdings said its product for non-healing diabetic foot ulcers met the primary endpoint in a recent trial. The medicine company said Monday that PuraPly plus standard of care (SOC) ...
Whole-blood transfusion has recently gained favor in the management of severe hemorrhage; however, data from large clinical trials evaluating its clinical effectiveness and safety are lacking. We ...
Statistically significant (pRCT compared PuraPly®AM plus standard of care to standard of care aloneResults strengthen existing clinical evidence supporting future coverage CANTON, Mass., April 06, ...
Investing.com -- Organogenesis Holdings Inc. (NASDAQ:ORGO) shares rose 20% Tuesday after the company announced its PuraPly AM product achieved the primary endpoint in a randomized controlled trial for ...
Limited today announced completion of its randomised controlled trial (RCT) evaluating Symphony, with a preliminary study read-out indicating the trial ...
Researchers at the University of California, Irvine have found that electroacupuncture may help improve cognitive function ...
Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced solid tumors: The TUXEDO-3 phase II trial.
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET) The median time post-HCT was ...
In an effort to increase access to evidence-based interventions to help manage anxiety and depression, Mass General Brigham ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results